Blockbuster Cancer Treatment Stymied by Supply Chain—for Now
J&J Revamps Drug Research, Plots Medical Device Deals
Big Pharma’s Battle With the Biden Administration Could Have Legs
Kenvue Stock Falls 6%, Drops Below IPO Price
Healthcare Stocks Push the Dow Higher
Stock Market News
Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact
J&J’s $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion
As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs
J&J Dividend Decision Shows Power of Free Cash Flow
Health Care Roundup: Market Talk
Johnson & Johnson Maintains Dividend After Kenvue Spinout
Johnson & Johnson Revises 2Q Results After Kenvue Split
Johnson & Johnson Adjusts Full-Year Outlook to Reflect Kenvue Split
Crypto Scores Big Win Over the SEC. Why the Battle’s Far From Over.
Johnson & Johnson 2Q Adj EPS $2.56 >JNJ
Kenvue Fits Right In With Other Dividend Aristocrats
Expensive Drugs Targeted for First U.S. Price Negotiations
The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List
First 10 Drugs Picked for Medicare Price Negotiations
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.